Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TXNDC16 | CTRPv2 | pan-cancer | AAC | 0.19 | 9e-09 |
mRNA | SALL2 | CTRPv2 | pan-cancer | AAC | 0.2 | 9e-09 |
mRNA | SHPRH | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-08 |
mRNA | UBTF | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-08 |
mRNA | ZNF292 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-08 |
mRNA | ZNF8 | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-08 |
mRNA | WTAP | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-08 |
mRNA | PHF14 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-08 |
mRNA | ZNF236 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-08 |
mRNA | SCAF8 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-08 |